Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version).
10.3760/cma.j.cn112338-20201111-01322
- Collective Name:Chinese Preventive Medicine Association;Vaccine and Immunology Branch of the Chinese Preventive Medicine Association
- Publication Type:Review
- Keywords:
Consensus;
Immunoprophylaxis;
Pneumococcal conjugate vaccine;
Pneumococcal disease;
Pneumococcal polysaccharide vaccine;
Streptococcus pneumoniae
- MeSH:
Adult;
Child;
China/epidemiology*;
Consensus;
Humans;
Pneumococcal Infections/prevention & control*;
Pneumococcal Vaccines/therapeutic use*;
Streptococcus pneumoniae/immunology*;
Vaccines, Conjugate/administration & dosage*
- From:Chinese Journal of Epidemiology
2020;41(12):1945-1979
- CountryChina
- Language:Chinese
-
Abstract:
Pneumococcal disease is a serious global public health problem and a leading cause of morbidity and mortality of children and adults in China. Antibiotics are commonly used to treat pneumococcal disease. However, antibiotic resistance to Streptococcus pneumoniae has become a severe problem around the world due to widespread antibiotic use. Immunoprophylaxis of pneumococcal disease with pneumococcal vaccines is therefore of great importance. In this article, we review the etiology, clinical presentation, epidemiology, and disease burden of pneumococcal disease and the vaccinology of pneumococcal vaccines. Our review is based on the Expert Consensus on Immunoprophylaxis of Pneumococcal Disease (2017 version), the Pneumococcal Vaccines WHO Position Paper (2019), and recent national and international scientific advances. This consensus article aims to provide public health and vaccination staff with appropriate evidence for pneumococcal vaccine use and to improve professional capacity for pneumococcal disease prevention and control.
